Thus, IFN-γ therapy can achieve better results with a time-dependent strategy and in combination with granulocyte–monocyte colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), or IL-7 and/or IL-15, which have the ability to enhance immune response, diminish secondary infections as well as improve long-term survival as sepsis recovery evolves [102]. The gene discussed is CSF2; the disease is Sepsis.